Literature DB >> 11562939

Annexin-1 is abnormally expressed in fragile X syndrome: two-dimensional electrophoresis study in lymphocytes.

H T Sun1, S Cohen, W E Kaufmann.   

Abstract

The search for targets of FMRP (the product of FMR1, the mutated gene in Fragile X syndrome) has predominantly focused on identifying transcripts that are regulated by this RNA-binding protein. This study introduces the use of two-dimensional gel electrophoresis (2D PAGE) as a novel approach for demonstrating changes in protein synthesis secondary to FMRP deficit. By a standardized 2D PAGE protocol, we studied leukocyte homogenates from 30 males with different patterns of FMR1 mutation and different levels of FMRP. Samples from these subjects were compared to those of 12 normal control males and eight subjects with other mental retardation-associated conditions (i.e., Rett and Down syndromes). We found an abnormal pattern of a major leukocytic protein, identified by 2D PAGE datasets and immunoblotting as annexin-1 (Anx-1). Anx-1 appeared in subjects with Fragile X as multiple rather than 1-2 spots, at approximately 37 kd, in the pI 5-7 range. The presence and intensity of this Anx-1 pattern was relatively independent of Anx-1 levels and inversely related to total and high MW FMRP immunoreactivities. Based on the 2D PAGE pattern, without obvious MW change, and on dephosphorylation assays, we concluded that Anx-1's abnormality represents an aberrant posttranslational modification other than phosphorylation. Comparisons of our data with published cytoskeletal protein 2D profiles suggest that Anx-1 may be abnormally acetylated and, consequently, incapable of establishing appropriate N-terminal protein-protein interactions. In addition to its peripheral anti-inflammatory function, Anx-1 mediates glucocorticoid inhibition of the hypothalamo-pituitary-adrenal axis. As the latter seems to be disrupted in Fragile X syndrome, the reported Anx-1 abnormality could be responsible for some aspects of the Fragile X neurobehavioral phenotype. Our data also emphasize the feasibility of using 2D PAGE for disclosing molecular abnormalities in Fragile X and other genetic disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562939     DOI: 10.1002/1096-8628(20010915)103:1<81::aid-ajmg1505>3.0.co;2-t

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  7 in total

1.  Proteome profiling of human epithelial ovarian cancer cell line TOV-112D.

Authors:  Jean-Philippe Gagné; Pierre Gagné; Joanna M Hunter; Marie-Eve Bonicalzi; Jean-François Lemay; Isabelle Kelly; Cécile Le Page; Diane Provencher; Anne-Marie Mes-Masson; Amaud Droit; David Bourgais; Guy G Poirier
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

2.  Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice.

Authors:  Mary E Blue; Walter E Kaufmann; Joseph Bressler; Charlotte Eyring; Cliona O'driscoll; Sakkubai Naidu; Michael V Johnston
Journal:  Anat Rec (Hoboken)       Date:  2011-09-08       Impact factor: 2.064

Review 3.  What can we learn about autism from studying fragile X syndrome?

Authors:  Dejan B Budimirovic; Walter E Kaufmann
Journal:  Dev Neurosci       Date:  2011-09-01       Impact factor: 2.984

4.  Protein targets of acrylamide adduct formation in cultured rat dopaminergic cells.

Authors:  Christopher J Martyniuk; April Feswick; Bin Fang; John M Koomen; David S Barber; Terrence Gavin; Richard M Lopachin
Journal:  Toxicol Lett       Date:  2013-04-06       Impact factor: 4.372

Review 5.  Annexin-A1: a pivotal regulator of the innate and adaptive immune systems.

Authors:  F D'Acquisto; M Perretti; R J Flower
Journal:  Br J Pharmacol       Date:  2008-07-21       Impact factor: 8.739

6.  Glucocorticoid regulation and neuroanatomy in fragile x syndrome.

Authors:  Jennifer L Bruno; David S Hong; Amy A Lightbody; S M Hadi Hosseini; Joachim Hallmayer; Allan L Reiss
Journal:  J Psychiatr Res       Date:  2020-12-11       Impact factor: 4.791

7.  Recurrent duplications of the annexin A1 gene (ANXA1) in autism spectrum disorders.

Authors:  Catarina T Correia; Inês C Conceição; Bárbara Oliveira; Joana Coelho; Inês Sousa; Ana F Sequeira; Joana Almeida; Cátia Café; Frederico Duque; Susana Mouga; Wendy Roberts; Kun Gao; Jennifer K Lowe; Bhooma Thiruvahindrapuram; Susan Walker; Christian R Marshall; Dalila Pinto; John I Nurnberger; Stephen W Scherer; Daniel H Geschwind; Guiomar Oliveira; Astrid M Vicente
Journal:  Mol Autism       Date:  2014-04-10       Impact factor: 7.509

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.